- About Pancreatic Cancer
- Get Support
Caregivers
- Get Involved
- Events
- More
2015-09
2017-09
2017-10
30
NCT02682394
Soroka University Medical Center
Soroka University Medical Center
OBSERVATIONAL
Evaluation of Pancreatic Steatosis in Patients With Cancer of Pancreas
Prognostic Importance of Quantitative Magnetic Resonance Imaging for Evaluation of Pancreatic Steatosis in Patients with Pancreatic Cancer
1. Finding patients with pancreatic cancer (in all stages), before any treatment. 2. Non invasively quantify fatty infiltration of pancreas using, MRI DIXON Scan in pancreatic cancer patient relatively to liver. 3. Measuring cell-free blood DNA in those patients for evaluating the aggressiveness of the disease. 4. Quantify the prognostic significance of pancreatic steatosis in comparison with clinical and pathological prognostic indexes used today.
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
| Study Registration Dates | Results Reporting Dates | Study Record Updates |
|---|---|---|
2015-12-28 | N/A | 2016-02-12 |
2016-02-12 | N/A | 2016-02-15 |
2016-02-15 | N/A | 2015-09 |
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Primary Purpose:
N/A
Allocation:
N/A
Interventional Model:
N/A
Masking:
N/A
Arms and Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|
| Primary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| Percentage of fat in pancreas measured in the head, body and tail excluding the lesion area. | measuring Pancreatic Steatosis in patients with pancreatic cancer using MRI DIXON scan, at 24 hours before chemotherapy starting. | at 24 hours before chemotherapy starting |
| Blood levels of free DNA | Correlation of free DNA level and metastatic spread. | The blood sample taken 15 minutes prior to MRI study, at time of IV access. |
| Secondary Outcome Measures | Measure Description | Time Frame |
|---|
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
|
Study Contact Name: Vladimir Borodetsky, MD Phone Number: +972547428882 Email: zivova1982@gmail.com |
Study Contact Backup Name: Irena Lazerev, MD Phone Number: +972526226458 Email: irinalaz@clalit.org.il |
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.
Ages Eligible for Study:
ALL
Sexes Eligible for Study:
18 Years
Accepts Healthy Volunteers:
This is where you will find people and organizations involved with this study.
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
No publications available
